Navigation Links
FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Date:4/25/2011

aths were reported during the study. Four percent of patients treated with 300 mg/day and 10 percent treated with 250 mg/day discontinued treatment due to adverse events. The only adverse event leading to withdrawal in more than one patient was rash (n=1 in 300mg/day, n=7 in 250 mg/day group).

Treatment-emergent adverse events were reported by 53 percent and 61 percent of patients in the 300 mg/day and 250 mg/day groups, respectively. The most common adverse events occurring in at least 5 percent of patients in either the 300 mg/day or 250 mg/day treatment group, respectively, were: headache (26 and 28 percent), dizziness (11 and 9 percent), rash (4 and 11 percent), nasopharyngitis (6 and 6 percent), nausea (5 and 5 percent), somnolence (4 and 5 percent) and insomnia (0 and 5 percent).

About LamictalXRLamictal XR Extended-Release Tablets are approved in the U.S. as adjunctive therapy for partial seizures and primary generalized tonic-clonic seizures in patients 13 years and older.  

Safety and effectiveness of Lamictal XR for use in patients less than 13 years of age have not been established.

Important Safety InformationPrescription Lamictal XR Extended-Release Tablets are not for everyone. LamictalXR may cause a serious skin rash that may cause patients to be hospitalized or to stop LamictalXR; it may rarely cause death. There is no way to tell if a mild rash will develop into a more serious reaction. These serious skin reactions are more likely to happen when patients begin taking Lamictal XR, within the first two to eight weeks of treatment. But it can happen in people who have taken Lamictal XR for any period of time. Children between 2 to 16 years of age have a higher chance of getting this serious skin reaction while taking lamotrigine. Lamictal XR is not ap
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
2. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
3. FDA Approves New Medical Device for Form of Brain Cancer
4. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
5. FDA Approves Horizant To Treat Restless Legs Syndrome
6. FDA Approves New Treatment for Rare Form of Thyroid Cancer
7. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
8. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
9. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
10. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
11. FDA Approves Gadavist for Central Nervous System Scans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... 5, 2015 GW Pharmaceuticals plc (Nasdaq: ... biopharmaceutical company focused on discovering, developing and commercializing ... announced today the closing of the previously announced ... of 1,600,000 American Depositary Shares (ADSs) at a ... of approximately $179.2 million (before deducting underwriting discount, ...
(Date:5/5/2015)... 2015 North American ophthalmology glaucoma ... 2014, and is estimated to grow to $138.3 million ... to 2019. Browse through the TOC of ... analysis of industry trends and segments, with the help ... Early buyers will receive 10% ...
Breaking Medicine Technology:GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos,Pharmaceuticals, ... the next generation of antiviral,therapeutic products, today ... that HIV resistant to Protease Inhibitors (PI) ... resistance to the HIV,maturation inhibitor bevirimat in ...
... Taxotere(R) and on three investigational,agents (VEGF Trap, S-1 ... ASCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ ... abstracts,indicative of its oncology commitment have been accepted ... of Clinical Oncology,(ASCO) in Chicago, Illinois (June 1-5, ...
Cached Medicine Technology:Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 2Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:5/5/2015)... (PRWEB) May 05, 2015 With ... Josie's Organics, one of the country's leading organic ... minds of moms across the country. What to ... family recipe box or spend hours browsing Pinterest ... on http://www.josiesorganics.com/recipes . , The new ...
(Date:5/5/2015)... RF Technologies®, a leading provider of ... Fall Management Solution with Voice Alarms. The ST750 will ... resident to wait for assistance when it detects them ... of 16 different melodies or tones or silent alerting, ... as Code Alert®. , For 28 years, Sensatec ...
(Date:5/5/2015)... What do you get when you combine ... greatest mountaineers and one of the world’s greatest causes? The ... documentary by Marc Middleton, which follows world-renowned mountaineer Chris Warner ... 19,341-foot frozen summit of Mount Kilimanjaro. , “This film ... to action. Viewers are moved to ask, ‘What can I ...
(Date:5/5/2015)... Sheltering Arms held its annual benefit event ... Cravath, Swaine & Moore LLP for their philanthropic leadership ... was co-chaired by Vanguard sponsors Morgan Stanley and Gail ... Sheltering Arms’ significant growth in New York City and ... Formerly Episcopal Social Services, Sheltering Arms has become of ...
(Date:5/5/2015)... Specialty makeup brand Beauty ... Outfitters on a collection of summer-oriented cosmetics and ... For the debut five-piece summer collection, Beauty For ... Eagle ; the retailer's fast-growing intimates, swim and ... REAL," uses models of various sizes and doesn't ...
Breaking Medicine News(10 mins):Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 2Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 3Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 4Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 2Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 3Health News:Sheltering Arms Honors Walt "Clyde" Frazier and Cravath, Swaine & Moore LLP at Annual Gala 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
... Pa., April 30 ViroPharma Incorporated,(Nasdaq: VPHM ) reported today ... Key events since December 31, 2007 include:, Development:, ... in stem cell transplant patients that enrollment ... May 2008; -- Patient enrollment continued in Phase 3 study ...
... Fla., April 30 Nihon LocalSoft, a ... the purpose of supporting US,Medical Device Manufactures ... entering the Japanese market, recently helped IRadimed,Corporation ... and localized embedded text for their operating ...
... Teeth,Whitening System(TM) has introduced an FDA cleared teeth ... look of discolored teeth. The company,created the procedure, ... addition to the spa experience. Now the process ... compromising the effectiveness,of the treatment., The Massage ...
... (NYSE: MYL ),today announced that in accordance with ... its quarterly dividend of $16.25 per,share (based on the ... $1,000.00 per share) payable on May 15, 2008, to ... 2008., Mylan Inc., with operations in more than ...
... Warner,Chilcott Limited (Nasdaq: WCRX ) today announced ... a securities class action lawsuit pending,in the United States ... suit asserted claims under the Securities Act of 1933 ... were allegedly damaged as a result of,acquiring the Company,s ...
Cached Medicine News:Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 2Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 3Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 4Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 5Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 6Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 7Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 8Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 9Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 10Health News:Nihon LocalSoft Designs New Japanese Software for IRadimed Corporation's Award-Winning MRidium MRI Infusion System 2Health News:Beautiful Teeth Not Just for the Dentist's Office Anymore / SpaBrite Teeth Whitening System(TM) Introduces Innovative, New Teeth Whitening Experience To Spas 2Health News:Warner Chilcott Announces Settlement of Securities Litigation 2Health News:Warner Chilcott Announces Settlement of Securities Litigation 3
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Seldin periosteal elevator #23, flat handle, 19.5 cm, 7-3/4"....
The CD Horizon Antares Spinal System represent a new addition to the CD Horizon Spinal System. It is based around a new, anatomically designed "pringle shaped" staple that allows for the placement of...
... a universal hook, rod, and screw system designed ... Moss Miami system utilizes a low profile design ... dual closure mechanism. The load sharing design of ... band principle to be applied when used with ...
Medicine Products: